June 02, 2026
Eli Lilly & Co. cited two circuit opinions this week as it defended the legality of halting the flow of discounted drugs under the 340B pricing program for safety net hospitals that won't hand over claims data. Law360 takes a closer look at the cases and decisions Eli Lilly is relying on.
May 21, 2024
The D.C. Circuit held Tuesday that a federal drug discount program does not bar manufacturers from restricting deliveries of discounted drugs to contract pharmacies, rejecting the U.S. Department of Health and Human Services' expansive interpretation of the 340B drug pricing program.